Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Upcoming June 2021 catalysts:
June 23rd-26th 2021: International Liver Congress 2021.
June 28th 2021: HEPA set to join Russell Microcap Index.
Any other ?
Am I right they have around 140mil in cash ? Might be possible for upcoming partnerships ???
Thanks for sharing good DD. I am going to add more shares monday..
$HEPA going to close HOD today and ready for a good Friday :)
Love this stock $PDSB
Not pumping , just sharing DD.
Couldn´t do it without you and the Solid DD.. $HEPA
Thanks. Updated the IBOX
Stickied this post :)
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Market cap: 177M
Outstanding: 76M
Employees: 12
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure, if this company can seem to pull off this cure (which I do not think it'll cure it but mitigate the disease) we can expect at least $30.
Currently trading at $2.2 due to a public offering of 44.000.000 shares @ $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
Well the places I post is not like WSB.
Serious investors with Diamond Hands that´s what we want for $HEPA
yes I am working on it on Reddit. Good to hear they notice :)
I am helping spreading your DD about $HEPA around the world.
Let me know in PM if you have something to add about this
$HEPA added 1000shares slapped on ask :)
Good to see some known investors here :) $HEPA
Fress bought more shares today. I just took my first starter here going to add more $HEPA
Nice I am helping with spreading the word on the streets..
$HEPA is undervalued!!!
Thanks for sharing your good DD about $HEPA.
I heard some rumors that this is a good buy, so I loaded some @ $2.19 today.
Diamond hands.
I just added more :)
A poster on stocktwits not sure if it´s true...
going to add this DIP!!!
This is a overreaction IMO..
Only 5.29 million shares. Should have minimal effect on SP
Kind of odd that someone bought so many shares EOD...
Like someone knew something... and then this offering ?
Nice volume here EOD... $PDSB...
Also Fress I have some free money , so if you have a good fresh pick beside $PDSB please drop me a PM
Back to 52w highs!!!
Go $PDSB $15 next
Oppenheimer- we raise our price target to $25 from $12. ASCO data flesh out compelling efficacy; PDSB to host virtual oncology R&D event on June 16th.
I think we will be over $20 again very soon!!! $THCB
What we all been waiting for!!!
Patience pays still red here , but diamond hands $THCB
Double digits coming... $PDSB
They will regret, thanks for the shares @ $9 yesterday...
They will regret, thanks for the shares @ $9 yesterday...
Diamond hands.. Again I´m so happy for your tip back in February.
Please PM me next time you have a new tip.
I will help support it 100% like I am doing with $PDSB!!!
Partner with nextgennk ?
https://ki.se/en/research/partners-0
Hi Fress, glad to hear from you and see that you are still here.
I added some @ $9 today aswell.
Today consolidation was needed due to quick move.
$PDSB
from pharmD on twitter
$PDSB
For a second try to digest how important this data is for R/R advanced HPV malignancies.
1) 1st line Chemo and or Radiation Tx, if fails followed by CI therapy.
2) ORR is about 12-24% with Checkpoint Inhibitors for R/R cancer that doesn’t respond to chemo/radiation tx.
3) BintraFusp alfa highest ORR so far close to 30% who are CI naive.
4) BintraFusp alfa showed ORR close to 10% in advanced HPV refractory to CI therapy.
5) Now PDS0101 triplet therapy shows an ORR of 10/14 (71%). Not sure why some biotech analysts ignoring this data
$PDSB Consolidation was needed.
We will be back in double digits and test new 52w high.
Hopefully my last add @ $9 will be ok.
Just got them before the halt.
Wonder why the sell off is happening.